rel-(1R,3R,5S)-3-Ethyl-1,5-dimethyl-6-azabicyclo[3.2.1]octane | 752200-24-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: rel-(1R,3R,5S)-3-Ethyl-1,5-dimethyl-6-azabicyclo[3.2.1]octane
• 英文别名: (1R,3R,5S)-3-ethyl-1,5-dimethyl-6-azabicyclo[3.2.1]octane
• CAS: 752200-24-1
• 化学式: C₁₁H₂₁N
• 分子量: 167.29
• InChiKey: BHEASCADYOYMLI-MXWKQRLJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists
  申请人：Parsons Graham Raphael Christopher

  公开号：US20060019982A1

  公开（公告）日：2006-01-26

  Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT 3 , and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.

  氨基环己烷的氮杂双环、氮杂三环和氮杂螺环衍生物，作为NMDA、5HT3和尼古丁受体拮抗剂具有系统活性，包括这些衍生物的制药组合物，其制备方法，以及用于治疗涉及谷氨酸能、血清素能和尼古丁能传递干扰的中枢神经系统疾病、治疗免疫调节性疾病、以及抗疟疾、抗锥虫病、抗Bornavirus、抗HSV和抗丙型肝炎病毒活性的方法。
• AZABICYCLIC, AZATRICYCLIC AND AZASPIROCYCLIC DERIVATIVES OF AMINOCYCLOHEXANE AS NMDA, 5HT3, AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS
  申请人：Merz Pharma GmbH & Co. KGaA

  公开号：EP1485086A1

  公开（公告）日：2004-12-15
• US7022729B2
  申请人：——

  公开号：US7022729B2

  公开（公告）日：2006-04-04
• US7238703B2
  申请人：——

  公开号：US7238703B2

  公开（公告）日：2007-07-03
• [EN] AZABICYCLIC, AZATRICYCLIC AND AZASPIROCYCLIC DERIVATIVES OF AMINOCYCLOHEXANE NMDA, 5HT3, AND NEURONAL NICOTINIC RECEPTOR ANTAGONI STS<br/>[FR] DERIVES AZABICYCLIQUES, AZATRICYCLIQUES ET AZASPIROCYCLIQUES D'AMINOCYCLOHEXANES COMME ANTAGONISTES DES RECEPTEURS DE NMDA, DES RECEPTEURS DE 5HT3 ET DES RECEPTEURS NICOTINIQUES NEURONAUX
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2003080046A1

  公开（公告）日：2003-10-02

  Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes of formula I (N, Y, Z,, R, R1-R5 as defined in the claims) which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.